 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
|
|
Conference Coverage
Thrombopoietin Receptor Agonists & Immune Thrombocytopenic Purpura (ITP): A Report from the 2007 American Society of Hematology (ASH) Meeting
Charles S. Abrams, MD, Associate Professor of Medicine, Director, Thrombophilia Program, University of Pennsylvania Health System, Philadelphia, Pennsylvania Supportive Care and Hematologic Malignancies: Updates from the 2007 American Society of Hematology
C. Dean Buckner, MD, Founding Member, Fred Hutchinson Cancer Research Center
|
| |
Current Topics
|
|
|
Latest
Immune Thrombocytopenic Purpura
News
Nplate® Approved for ITP (8/25/2008)
Amgen’s platelet simulator Nplate® (romiplostim) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic immune thrombocytopenic purpura (ITP) who are refractory to standard therapy.
ODAC Recommends Approval of Nplate (7/15/2008)
The Oncology Drugs Advisory Committee (ODAC), which provides recommendations to the U.S. Food and Drug Administration (FDA), has recommended the approval of Nplate™ (romiplostim) for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
|
|
Newsletters
Register in our member center today to receive a monthly newsletter with clinical
news, conference coverage, and current topic updates.
|
|
|
|
|
|
Patient Home
